Naslov
Erlotinib-related rhabdomyolysis: the role of pharmacogenetics and drug-drug interaction

Autori
Koršić, Marta ; Muršić, Davorka ; Badovinac, Sonja ; Božina, Nada ; Roglić, Mihovil ; Jakopović, Marko ; Čučević, Branka

Izvornik
Cancer chematotherapy and pharmacology (0344-5704) 76 (2015), 6; 1317-1319

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, pismo uredniku, znanstveni

Ključne riječi
Erlotinib-related rhabdomyolysis ; pharmacogenetics

Sažetak
Interindividual pharmacokinetic variability of erlotinib is affected not only by the genetic heterogeneity of drug targets, but also by patient's pharmacogenetic background. Erlotinib is mainly metabolized by cytochrome P450 (CYP) 3A4 isoenzyme and is transported across different barriers by P-glycoprotein and ABCG2 drug transporters. The presented case suggests that erlotinib may cause rhabdomyolysis in a small proportion of patients who have pharmacogenetic predisposition and take interacting concomitant medication. In described case interaction occurred on the level of drug metabolism and transport, which considerably prolonged erlotinib biodisposition and resulted in adverse drug reaction.

Izvorni jezik
Engleski

POVEZANOST RADA